Primary sclerosing cholangitis is a rare liver complication that can develop among people with inflammatory bowel disease. Early diagnosis can help, but there’s no cure.

Ahead of New York Fashion Week, Gilead Sciences is strutting its marketing stuff to raise awareness of primary biliary ...

Intercept Pharmaceuticals has voluntarily pulled Ocaliva (obeticholic acid) from the US market following a request from the ...

Intercept Pharmaceuticals has pulled obeticholic acid (Ocaliva) from the U.S. market as a treatment for primary biliary ...

Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its ...

Primary sclerosing cholangitis is a rare, unpreventable liver complication that can happen among people with inflammatory bowel disease.

Discover a study exploring how verbal instructions and symptom expectations influence fatigue and motivation in people living with primary biliary cholangitis.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of ...

Topline data were announced from a phase 2b/3 trial evaluating saroglitazar in patients with PBC who had an inadequate response or intolerance to UDCA.

FDA arrives at its rejections for a variety of reasons, though typically due to concerns over safety, effectiveness, or a problem with manufacturing. Issues with efficacy may require new analyses or ...

Crohn’s disease is a chronic autoimmune inflammatory disorder affecting the gastrointestinal tract. It is characterized by a ...

Rheumatoid arthritis has traditionally been framed as a self-contained autoimmune disease confined to joints, yet mounting ...